Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Sullivan

Showing results (61-70 of 106) with videos related to

Pageof 11
Sort By:
Diabetes Research and Clinical Practice|March 13, 2025
Relationship of haptoglobin phenotype and levels with sight-threatening diabetic retinopathy in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in diabetes (FIELD) substudyKwok Leung Ong, Andrzej S Januszewski, Habib Francis, et al.
Atherosclerosis|September 4, 2007
Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South AfricaVivienne M Homer, A David Marais, Francesca Charlton, et al.
The Medical Journal of Australia|October 7, 2006
Health benefits of herbs and spices: the past, the present, the futureLinda C Tapsell, Ian Hemphill, Lynne Cobiac, et al.
Diabetes, Obesity & Metabolism|April 4, 2020
Uric acid predicts long-term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD studyJacob Y Cao, Boris Waldman, Rachel O'Connell, et al.
Diabetologia|June 10, 2015
Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes studyKwok-Leung Ong, Andrzej S Januszewski, Rachel O'Connell, et al.
European Journal of Preventive Cardiology|September 19, 2025
The association of haptoglobin levels and phenotype with cardiovascular disease in Type 2 diabetes: a Fenofibrate Intervention and Event Lowering in Diabetes sub-studyKwok Leung Ong, Andrzej S Januszewski, Habib Francis, et al.
Diabetes/Metabolism Research and Reviews|March 9, 2023
Factors associated with fragility fractures in type 2 diabetes: An analysis of the randomised controlled Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) studyAngela Sheu, Rachel L O'Connell, Alicia J Jenkins, et al.
Diabetologia|November 27, 2014
The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes studyKwok-Leung Ong, Andrzej S Januszewski, Rachel O'Connell, et al.
Journal of Diabetes Investigation|August 22, 2024
Haptoglobin phenotype and levels in type 2 diabetes and effects of fenofibrateAndrzej S Januszewski, Hayden K Young, Kwok-Leung Ong, et al.
Australian Journal of General Practice|September 1, 2022
Participant experiences of intervention to detect and manage familial hypercholesterolaemia in Australian general practice: A qualitative descriptive studyRachel Skoss, Tom Brett, Caroline Bulsara, et al.
Pageof 11

Showing results (61-70 of 106) with videos related to

Sort By:
Pageof 11
Diabetes Research and Clinical Practice|March 13, 2025
Relationship of haptoglobin phenotype and levels with sight-threatening diabetic retinopathy in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in diabetes (FIELD) substudyKwok Leung Ong, Andrzej S Januszewski, Habib Francis, et al.
Atherosclerosis|September 4, 2007
Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South AfricaVivienne M Homer, A David Marais, Francesca Charlton, et al.
The Medical Journal of Australia|October 7, 2006
Health benefits of herbs and spices: the past, the present, the futureLinda C Tapsell, Ian Hemphill, Lynne Cobiac, et al.
Diabetes, Obesity & Metabolism|April 4, 2020
Uric acid predicts long-term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD studyJacob Y Cao, Boris Waldman, Rachel O'Connell, et al.
Diabetologia|June 10, 2015
Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes studyKwok-Leung Ong, Andrzej S Januszewski, Rachel O'Connell, et al.
European Journal of Preventive Cardiology|September 19, 2025
The association of haptoglobin levels and phenotype with cardiovascular disease in Type 2 diabetes: a Fenofibrate Intervention and Event Lowering in Diabetes sub-studyKwok Leung Ong, Andrzej S Januszewski, Habib Francis, et al.
Diabetes/Metabolism Research and Reviews|March 9, 2023
Factors associated with fragility fractures in type 2 diabetes: An analysis of the randomised controlled Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) studyAngela Sheu, Rachel L O'Connell, Alicia J Jenkins, et al.
Diabetologia|November 27, 2014
The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes studyKwok-Leung Ong, Andrzej S Januszewski, Rachel O'Connell, et al.
Journal of Diabetes Investigation|August 22, 2024
Haptoglobin phenotype and levels in type 2 diabetes and effects of fenofibrateAndrzej S Januszewski, Hayden K Young, Kwok-Leung Ong, et al.
Australian Journal of General Practice|September 1, 2022
Participant experiences of intervention to detect and manage familial hypercholesterolaemia in Australian general practice: A qualitative descriptive studyRachel Skoss, Tom Brett, Caroline Bulsara, et al.
Pageof 11